IL202758A - Pyrol derivatives as p2y12 antagonists - Google Patents

Pyrol derivatives as p2y12 antagonists

Info

Publication number
IL202758A
IL202758A IL202758A IL20275809A IL202758A IL 202758 A IL202758 A IL 202758A IL 202758 A IL202758 A IL 202758A IL 20275809 A IL20275809 A IL 20275809A IL 202758 A IL202758 A IL 202758A
Authority
IL
Israel
Prior art keywords
compounds
formula
adp receptor
platelet adp
antagonists
Prior art date
Application number
IL202758A
Other languages
English (en)
Hebrew (he)
Other versions
IL202758A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL202758A0 publication Critical patent/IL202758A0/en
Publication of IL202758A publication Critical patent/IL202758A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL202758A 2007-06-18 2009-12-15 Pyrol derivatives as p2y12 antagonists IL202758A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290755 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (2)

Publication Number Publication Date
IL202758A0 IL202758A0 (en) 2010-06-30
IL202758A true IL202758A (en) 2013-09-30

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202758A IL202758A (en) 2007-06-18 2009-12-15 Pyrol derivatives as p2y12 antagonists

Country Status (12)

Country Link
US (1) US7910576B2 (https=)
EP (1) EP2167487B1 (https=)
JP (1) JP5371969B2 (https=)
KR (1) KR20100020478A (https=)
CN (1) CN101679358B (https=)
AU (1) AU2008266515B2 (https=)
BR (1) BRPI0812912A2 (https=)
CA (1) CA2690243A1 (https=)
IL (1) IL202758A (https=)
MX (1) MX2009013431A (https=)
MY (1) MY148901A (https=)
WO (1) WO2008155022A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090073231A (ko) 2006-10-20 2009-07-02 노파르티스 아게 ３-(１ｈ-인돌-３-일)-４-[２-(４-메틸-피페라진-１-일)-퀴나졸린-４-일]-피롤-２,５-디온의 결정 변체
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN121108187A (zh) 2019-04-03 2025-12-12 阿里戈斯治疗公司 吡咯化合物
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7273881B2 (en) * 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法
EP1836189A1 (en) * 2005-01-06 2007-09-26 AstraZeneca AB Novel pyridine compounds
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
CA2603041A1 (en) * 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
WO2007103456A2 (en) * 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Also Published As

Publication number Publication date
CN101679358A (zh) 2010-03-24
AU2008266515B2 (en) 2014-05-01
US7910576B2 (en) 2011-03-22
CN101679358B (zh) 2013-10-30
KR20100020478A (ko) 2010-02-22
CA2690243A1 (en) 2008-12-24
JP5371969B2 (ja) 2013-12-18
JP2010530380A (ja) 2010-09-09
MY148901A (en) 2013-06-14
EP2167487A1 (en) 2010-03-31
AU2008266515A1 (en) 2008-12-24
WO2008155022A1 (en) 2008-12-24
MX2009013431A (es) 2010-01-15
HK1142593A1 (en) 2010-12-10
BRPI0812912A2 (pt) 2014-12-09
US20100226918A1 (en) 2010-09-09
IL202758A0 (en) 2010-06-30
EP2167487B1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
MX2009011089A (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
WO2009080226A3 (en) Heterocyclic pyrazole-carboxamides as p2y12 antagonists
WO2009080227A3 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
GEP20156285B (en) Compounds and compositions as trk inhibitors
SG10201906942PA (en) Piperidine cxcr7 receptor modulators
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
WO2009010454A3 (en) Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
MX2013001805A (es) Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1.
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
MY148634A (en) Pyridazinone derivatives
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
PH12012500752A1 (en) Benzimidazole-imidazole derivatives
MY166866A (en) Heterocyclic derivative and pharmaceutical drug
TW200806300A (en) New therapeutic combinations for the treatment of depression
MX2009004686A (es) Acido l-glutamico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, asi como procedimientos para su preparacion.
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
TW200612936A (en) Indole derivatives
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
IL202758A (en) Pyrol derivatives as p2y12 antagonists
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees